Table 1.
Baseline patient and treatment characteristics (N=28)a
| Characteristics | N (%)b |
|---|---|
| Age at ICI treatment - years | |
| Median (range) | 78 years (66–93) |
| Sex | |
| Male | 19 (69) |
| Females | 9 (31) |
| Race/ethnicity | |
| Caucasian | 26 (93) |
| African American | 2 (7) |
| Household composition | |
| Lives alone | 9 (32) |
| Lives with spouse, partner or child | 13 (46) |
| Unknown | 6 (21) |
| ECOG performance status | |
| 0–1 | 11 (39) |
| 2–3 | 17 (60) |
| Cancer Type | |
| Lung | 11 (39) |
| Melanoma | 5 (18) |
| GU | 8 (28) |
| GI | 2 (7) |
| Other | 2 (7) |
| Stage | |
| III | 3 (11) |
| IV | 25 (89) |
| Prior chemotherapy | |
| No | 12 (43) |
| Yes | 16 (57) |
| ICI Agent | |
| Pembrolizumab | 14 (50) |
| Nivolumab | 9 (32) |
| Atezolizumab | 3 (10) |
| Ipilimumab | 2 (7) |
| Line of therapy (ICI) | |
| First line | 12 (43) |
| Second line | 10 (36) |
| Third line | 3 (11) |
| Fourth line | 3 (11) |
Abbreviations: ECOG, Eastern Collaborative Oncology Group; GI, gastrointestinal; GU, genitourinary
a
Data expressed as N (%) unless otherwise specified.
b
Due to rounding, percentages may not always add up to 100%